Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–57 of 57 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia
Interventions
Luvadaxistat, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Atomoxetine (Strattera)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Negative Symptoms of Schizophrenia
Interventions
Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
Conditions
Schizophrenia
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Cerritos, California • Garden Grove, California • National City, California + 14 more
Conditions
Schizophrenia
Interventions
AMG 747, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Long Beach, California + 14 more
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Conditions
Schizophrenia
Interventions
LY500307 150mg, LY500307 75mg, Placebo, LY500307 25mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Indianapolis, Indiana
Conditions
Schizophrenia
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania